Quantbot Technologies LP Purchases Shares of 53,503 Hologic, Inc. $HOLX

Quantbot Technologies LP acquired a new position in shares of Hologic, Inc. (NASDAQ:HOLX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 53,503 shares of the medical equipment provider’s stock, valued at approximately $3,611,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Winnow Wealth LLC acquired a new stake in Hologic in the 3rd quarter valued at approximately $26,000. Root Financial Partners LLC bought a new position in shares of Hologic in the third quarter worth $27,000. SJS Investment Consulting Inc. increased its holdings in shares of Hologic by 341.5% during the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 362 shares during the period. Loomis Sayles & Co. L P acquired a new position in shares of Hologic during the second quarter valued at $33,000. Finally, Smartleaf Asset Management LLC raised its stake in shares of Hologic by 168.5% during the third quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 310 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Price Performance

NASDAQ HOLX opened at $75.36 on Monday. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $75.49. The business’s fifty day moving average is $74.95 and its two-hundred day moving average is $72.16. The stock has a market capitalization of $16.82 billion, a P/E ratio of 31.40, a P/E/G ratio of 2.24 and a beta of 0.72. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.The business’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.87 earnings per share. On average, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on HOLX. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Evercore lowered shares of Hologic from an “outperform” rating to an “in-line” rating and reduced their price target for the stock from $79.00 to $78.00 in a research note on Monday, January 5th. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. BNP Paribas Exane cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a report on Friday, November 21st. Finally, Morgan Stanley upped their target price on Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Two research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $78.42.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.